Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial
Titel:
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial
Auteur:
Wu, Yi-Long Cheng, Ying Zhou, Jianying Lu, Shun Zhang, Yiping Zhao, Jun Kim, Dong-Wan Soo, Ross Andrew Kim, Sang-We Pan, Hongming Chen, Yuh-Min Chian, Chih-Feng Liu, Xiaoqing Tan, Daniel Shao Weng Bruns, Rolf Straub, Josef Johne, Andreas Scheele, Jürgen Park, Keunchil Yang, James Chih-Hsin